Early relations with regulators key to solving innovation problem
This article was originally published in SRA
Executive Summary
One of the most important contributions the pharmaceutical industry can make to improving innovation and reducing the chance of costly trials failing is to align itself earlier with key stakeholders, such as drug regulators and reimbursement bodies, Professor Stuart Walker, founder of CMR International Institute for Regulatory Science, told delegates at the 7th annual meeting of The Organisation for Professionals in Regulatory Affairs in London on 4-6 October.